Get the Stockscreener App
62.28
0.56%
-0.3522
After Hours:
62.42
0.1405
+0.23%
Invesco Biotechnology Genome Etf Stock (PBE) Forecast
The Invesco Biotechnology Genome Etf (PBE) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $68.41, representing a +9.84% increase from the current price of $62.28. The highest analyst price target is $72.56, and the lowest is $64.26.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month PBE Price Target
Average 81.38
(+30.67% Upside)
Is Invesco Biotechnology Genome Etf (PBE) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 53.30 | Neutral |
| STOCH(9,6) | 90.50 | Sell |
| STOCHRSI(14) | 89.26 | Sell |
| MACD(12,26) | -0.1595 | Buy |
| ADX(14) | 28.14 | Sell |
| William %R | -11.95 | Sell |
| CCI(14) | 64.88 | Neutral |
Buy: 1
Sell: 4
Neutral: 2
Summary: Sell
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
61.43
Buy
|
61.50
Buy
|
| MA20 |
59.98
Buy
|
61.30
Buy
|
| MA50 |
63.10
Sell
|
62.82
Sell
|
| MA100 |
65.71
Sell
|
64.70
Sell
|
| MA200 |
67.63
Sell
|
65.70
Sell
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, PBE could be considered a Strong Sell, with 17 technical analysis indicators signaling 5 Buy signals, 10 signaling Sell signals and 2 Neutral signals. This might not be a good time to consider opening new positions on PBE, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 53.3 indicates that PBE is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 90.5 indicates that PBE is oversold. This means that PBE price is at or near the highest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 89.26 indicates that PBE is oversold. This suggests that PBE price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 28.14 suggests a moderate trend in the market. While not exceptionally strong, it indicates that there is some directional movement occurring. You should pay attention to this trend but may also look for confirmation from other technical indicators or fundamental factors.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 64.88 indicates that PBE is still overbought but not to an extreme extent.
Long-term PBE price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Invesco Biotechnology Genome Etf financial reports and earnings history, Invesco Biotechnology Genome Etf (PBE) stock could reach $76.17 by 2030, $109.88 by 2040 and $133.90 by 2050. See the projected annual prices until 2050 of the Invesco Biotechnology Genome Etf stock below:
- Invesco Biotechnology Genome Etf (PBE) is expected to reach an average price of $87.61 in 2035, with a high prediction of $87.85 and a low estimate of $83.25. This indicates an $40.68% rise from the last recorded price of $62.28.
- Invesco Biotechnology Genome Etf (PBE) stock is projected to chart a bullish course in 2040, with an average price target of $107.66, representing an $72.86% surge from its current level. The forecast ranges from a conservative $105.90 to a sky-high $109.88.
- Our analysts predict Invesco Biotechnology Genome Etf (PBE) to jump 89.96% by 2045, soaring from $114.90 to an average price of $118.31, potentially reaching $121.81. While $114.90 is the low estimate, the potential upside is significant.
- Invesco Biotechnology Genome Etf (PBE) stock is expected to climb by 2050, reaching an average of $133.90, a $115.00% jump from its current level. However, a wide range of estimates exists, with high and low targets of $133.90 and $128.23, respectively, highlighting the market's uncertainty.
Invesco Biotechnology Genome Etf Stock (PBE) Year by Year Forecast
Invesco Biotechnology Genome Etf Stock (PBE) Price Forecast for 2025
Invesco Biotechnology Genome Etf Stock (PBE) is expected to reach an average price of $63.92 in 2025, with a high prediction of $76.70 and a low estimate of $51.15. This indicates an +2.64% rise from the last recorded price of $62.28.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| June, 2025 | $70.41 | $64.26 | $72.56 | +13.05% |
| July, 2025 | $70.60 | $66.15 | $72.36 | +13.36% |
| August, 2025 | $73.14 | $69.28 | $74.50 | +17.44% |
| September, 2025 | $74.49 | $71.08 | $76.70 | +19.60% |
| October, 2025 | $67.73 | $65.68 | $74.70 | +8.75% |
| November, 2025 | $70.03 | $66.65 | $71.28 | +12.45% |
| December, 2025 | $70.01 | $69.59 | $75.94 | +12.41% |
Invesco Biotechnology Genome Etf Stock (PBE) Price Forecast for 2026
The predicted value for Invesco Biotechnology Genome Etf (PBE) in 2026 is set at an average of $83.86. Estimates vary from a peak of $98.50 to a trough of $69.23, indicating an +34.65% surge from the present price of $62.28.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $77.10 | $69.23 | $77.30 | +23.79% |
| February, 2026 | $84.38 | $76.76 | $84.88 | +35.49% |
| March, 2026 | $89.73 | $83.13 | $91.09 | +44.08% |
| April, 2026 | $92.73 | $86.04 | $98.50 | +48.89% |
| May, 2026 | $88.82 | $80.84 | $93.75 | +42.62% |
| June, 2026 | $86.67 | $83.94 | $90.61 | +39.17% |
| July, 2026 | $84.92 | $81.27 | $92.65 | +36.35% |
| August, 2026 | $91.04 | $83.69 | $91.79 | +46.18% |
| September, 2026 | $90.96 | $89.30 | $93.14 | +46.05% |
| October, 2026 | $90.85 | $84.89 | $91.45 | +45.88% |
| November, 2026 | $92.46 | $88.17 | $92.89 | +48.45% |
| December, 2026 | $88.86 | $88.41 | $93.90 | +42.68% |
Invesco Biotechnology Genome Etf Stock (PBE) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Invesco Biotechnology Genome Etf (PBE) is $78.66, with a high forecast of $91.45 and a low forecast of $65.87. This indicates an +26.30% increase from the last price of $62.28.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $89.10 | $86.91 | $89.33 | +43.07% |
| February, 2027 | $87.49 | $85.72 | $91.45 | +40.48% |
| March, 2027 | $85.39 | $79.29 | $87.57 | +37.11% |
| April, 2027 | $78.14 | $76.32 | $86.98 | +25.47% |
| May, 2027 | $74.26 | $70.67 | $77.57 | +19.24% |
| June, 2027 | $72.60 | $69.93 | $77.10 | +16.58% |
| July, 2027 | $76.37 | $70.96 | $77.62 | +22.62% |
| August, 2027 | $73.44 | $73.44 | $78.83 | +17.92% |
| September, 2027 | $73.15 | $66.23 | $73.94 | +17.46% |
| October, 2027 | $68.63 | $65.87 | $73.46 | +10.19% |
| November, 2027 | $76.47 | $68.69 | $76.47 | +22.79% |
| December, 2027 | $80.59 | $73.80 | $81.71 | +29.41% |
Invesco Biotechnology Genome Etf Stock (PBE) Price Forecast for 2028
In 2028, Invesco Biotechnology Genome Etf (PBE) is projected to reach an average price of $77.17, with a high projection of $83.38 and a low estimate of $70.96. This indicates an +23.91% rise from the last price of $62.28.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $74.60 | $74.36 | $81.36 | +19.79% |
| February, 2028 | $73.60 | $70.96 | $77.90 | +18.17% |
| March, 2028 | $78.14 | $73.21 | $78.78 | +25.47% |
| April, 2028 | $79.66 | $76.90 | $80.83 | +27.90% |
| May, 2028 | $78.19 | $77.99 | $82.89 | +25.54% |
| June, 2028 | $82.10 | $76.78 | $82.75 | +31.83% |
| July, 2028 | $80.42 | $80.05 | $83.38 | +29.13% |
| August, 2028 | $75.38 | $74.73 | $81.08 | +21.03% |
| September, 2028 | $79.09 | $74.97 | $79.12 | +26.99% |
| October, 2028 | $78.23 | $75.86 | $79.88 | +25.61% |
| November, 2028 | $77.14 | $74.99 | $79.41 | +23.86% |
| December, 2028 | $76.41 | $74.78 | $78.89 | +22.69% |
Invesco Biotechnology Genome Etf Stock (PBE) Price Forecast for 2029
The 2029 price forecast for Invesco Biotechnology Genome Etf Stock (PBE) is $75.57 on average, with a high prediction of $83.33 and a low estimate of $67.80. This represents an +21.33% increase from the previous price of $62.28.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $78.63 | $74.82 | $79.32 | +26.25% |
| February, 2029 | $76.07 | $75.14 | $77.88 | +22.15% |
| March, 2029 | $74.35 | $74.29 | $77.52 | +19.38% |
| April, 2029 | $71.79 | $70.49 | $74.38 | +15.27% |
| May, 2029 | $69.28 | $67.80 | $73.09 | +11.24% |
| June, 2029 | $75.15 | $68.74 | $75.15 | +20.67% |
| July, 2029 | $81.29 | $74.94 | $82.55 | +30.52% |
| August, 2029 | $79.81 | $79.26 | $82.51 | +28.15% |
| September, 2029 | $80.14 | $77.39 | $80.63 | +28.68% |
| October, 2029 | $80.47 | $79.27 | $83.33 | +29.21% |
| November, 2029 | $75.49 | $74.96 | $80.81 | +21.21% |
| December, 2029 | $75.41 | $74.30 | $79.19 | +21.08% |
Invesco Biotechnology Genome Etf Stock (PBE) Price Forecast for 2030
Invesco Biotechnology Genome Etf Stock (PBE) is expected to reach an average price of $73.90 in 2030, with a high forecast of $83.58 and a low forecast of $64.22. This signifies an +18.66% surge from the last price of $62.28.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $75.48 | $73.48 | $76.17 | +21.19% |
| February, 2030 | $77.48 | $75.38 | $79.59 | +24.41% |
| March, 2030 | $78.51 | $77.21 | $80.43 | +26.06% |
| April, 2030 | $75.37 | $74.64 | $79.43 | +21.01% |
| May, 2030 | $73.36 | $72.55 | $76.13 | +17.79% |
| June, 2030 | $75.79 | $71.33 | $76.63 | +21.69% |
| July, 2030 | $79.10 | $75.94 | $79.13 | +27.01% |
| August, 2030 | $82.32 | $79.43 | $82.55 | +32.18% |
| September, 2030 | $81.41 | $80.76 | $82.58 | +30.72% |
| October, 2030 | $82.32 | $79.85 | $83.58 | +32.18% |
| November, 2030 | $69.10 | $66.87 | $82.57 | +10.95% |
| December, 2030 | $71.37 | $64.22 | $73.41 | +14.59% |
0.51%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):